{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:37:58Z","timestamp":1793644678183,"version":"4.5.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,6,23]],"date-time":"2007-06-23T00:00:00Z","timestamp":1182556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2007,9,19]]},"DOI":"10.1007\/s00213-007-0821-0","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T04:22:19Z","timestamp":1182486139000},"page":"233-242","source":"Crossref","is-referenced-by-count":58,"title":["A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder"],"prefix":"10.1007","volume":"194","author":[{"given":"Mark","family":"Pollack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Entsuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Tzanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,23]]},"reference":[{"key":"821_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.179.1.15","volume":"179","author":"C Allgulander","year":"2001","unstructured":"Allgulander C, Hackett D, Salinas E (2001) Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15\u201322","journal-title":"Br J Psychiatry"},{"key":"821_CR2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","volume":"19","author":"C Allgulander","year":"2004","unstructured":"Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387\u2013396","journal-title":"Hum Psychopharmacol"},{"key":"821_CR3","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM-IV), 4th edn (revised). Washington, DC"},{"key":"821_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.155.1.1","volume":"155","author":"American Psychiatric Association","year":"1998","unstructured":"American Psychiatric Association (1998) Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry 155:1\u201334","journal-title":"Am J Psychiatry"},{"key":"821_CR5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","volume":"19","author":"DS Baldwin","year":"2005","unstructured":"Baldwin DS,Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Wittchen HU, British Association for Psychopharmacology (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567\u2013596","journal-title":"J Psychopharmacol"},{"key":"821_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/JCP.v59n0201","volume":"59","author":"JC Ballenger","year":"1998","unstructured":"Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK (1998a) Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59:47\u201354","journal-title":"J Clin Psychiatry"},{"key":"821_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","volume":"155","author":"JC Ballenger","year":"1998","unstructured":"Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998b) Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36\u201342","journal-title":"Am J Psychiatry"},{"key":"821_CR8","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1001\/jama.283.19.2529","volume":"283","author":"D Barlow","year":"2000","unstructured":"Barlow D, Gorman J, Shear M, Woods S (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 283:2529\u20132536","journal-title":"JAMA"},{"key":"821_CR9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-2004-832593","volume":"37","author":"A Bertani","year":"2004","unstructured":"Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L (2004) Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37:206\u2013210","journal-title":"Pharmacopsychiatry"},{"key":"821_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archpsyc.1993.01820130046008","volume":"50","author":"DW Black","year":"1993","unstructured":"Black DW, Wesner R, Bowers W, Gabel J (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44\u201350","journal-title":"Arch Gen Psychiatry"},{"key":"821_CR11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","volume":"187","author":"J Bradwejn","year":"2005","unstructured":"Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T (2005) Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352\u2013359","journal-title":"Br J Psychiatry"},{"key":"821_CR12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/hup.421","volume":"17","author":"PN Dannon","year":"2002","unstructured":"Dannon PN, Iancu I, Grunhaus L (2002) The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17:329\u2013333","journal-title":"Hum Psychopharmacol"},{"key":"821_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S1461145705006413","volume":"10","author":"G Debonnel","year":"2007","unstructured":"Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 10:51\u201361","journal-title":"Int J Neuropsychopharmacol"},{"key":"821_CR14","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","volume":"283","author":"AJ Gelenberg","year":"2000","unstructured":"Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283:3082\u20133088","journal-title":"JAMA"},{"key":"821_CR15","first-page":"408","volume":"56","author":"TD Geracioti Jr","year":"1995","unstructured":"Geracioti TD Jr (1995) Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 56:408\u2013410","journal-title":"J Clin Psychiatry"},{"key":"821_CR16","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1176\/appi.ajp.159.10.1702","volume":"159","author":"ML Gilmor","year":"2002","unstructured":"Gilmor ML, Owens MJ, Nemeroff CB (2002) Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159:1702\u20131710","journal-title":"Am J Psychiatry"},{"issue":"4","key":"821_CR17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.euroneuro.2005.04.006","volume":"15","author":"RD Goodwin","year":"2005","unstructured":"Goodwin RD, Faravelli C, Rosi S, Cosci F, Truglia E, de Graaf R, Wittchen HU (2005) The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol 15(4):435\u2013443","journal-title":"Eur Neuropsychopharmacol"},{"key":"821_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","volume":"157","author":"JM Gorman","year":"2000","unstructured":"Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000) Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:493\u2013505","journal-title":"Am J Psychiatry"},{"key":"821_CR19","doi-asserted-by":"crossref","unstructured":"Guy W (ed) (1976) ECDEU Assessment Manual for Psychopharmacology (revised). National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD","DOI":"10.1037\/e591322011-001"},{"key":"821_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56\u201362","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"821_CR21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","volume":"75","author":"Y Hochberg","year":"1988","unstructured":"Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800\u2013809","journal-title":"Biometrika"},{"key":"821_CR22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2165\/00003495-199549030-00002","volume":"49","author":"MR Johnson","year":"1995","unstructured":"Johnson MR, Lydiard RB, Ballenger JC (1995) Panic disorder. Pathophysiology and drug treatment. Drugs 49:328\u2013344","journal-title":"Drugs"},{"key":"821_CR23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1192\/bjp.167.4.487","volume":"167","author":"H Katschnig","year":"1995","unstructured":"Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M (1995) Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 167:487\u2013494","journal-title":"Br J Psychiatry"},{"key":"821_CR24","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/00004714-199606002-00005","volume":"16","author":"JE Kelsey","year":"1996","unstructured":"Kelsey JE (1996) Dose-response relationship with venlafaxine. J Clin Psychopharmacol 16:21S\u201326S","journal-title":"J Clin Psychopharmacol"},{"key":"821_CR25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","volume":"63","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE (2006) The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. Arch Gen Psychiatry 63:415\u2013424","journal-title":"Arch Gen Psychiatry"},{"key":"821_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004714-199802000-00004","volume":"18","author":"A Khan","year":"1998","unstructured":"Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM (1998) The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 18:19\u201325","journal-title":"J Clin Psychopharmacol"},{"key":"821_CR27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0028-3908(03)00268-5","volume":"45","author":"S Koch","year":"2003","unstructured":"Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP (2003) Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45:935\u2013944","journal-title":"Neuropharmacology"},{"issue":"Suppl 3","key":"821_CR28","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/S0924-977X(04)80386-9","volume":"14","author":"MR Liebowitz","year":"2004","unstructured":"Liebowitz MR, Asnis G, Tzanis E, Whitaker T (2004) A double-blind, placebo-controlled trial of venlafaxine XR in the short-term treatment of panic disorder [abstract]. Eur Neuropsychopharmacol 14(Suppl 3):S305\u2013S306","journal-title":"Eur Neuropsychopharmacol"},{"key":"821_CR29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","volume":"62","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Gelenberg AJ, Munjack D (2005a) Venlafaxine vs paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190\u2013198","journal-title":"Arch Gen Psychiatry"},{"key":"821_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","volume":"66","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005b) A Randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238\u2013247","journal-title":"J Clin Psychiatry"},{"key":"821_CR31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","volume":"173","author":"PD Londborg","year":"1998","unstructured":"Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C (1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54\u201360","journal-title":"Br J Psychiatry"},{"key":"821_CR32","first-page":"258","volume":"7","author":"RB Lydiard","year":"1987","unstructured":"Lydiard RB (1987) Desipramine in agoraphobia with panic attacks: an open, fixed-dose study. J Clin Psychopharmacol 7:258\u2013260","journal-title":"J Clin Psychopharmacol"},{"key":"821_CR33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/archpsyc.1989.01810110026004","volume":"46","author":"JS Markowitz","year":"1989","unstructured":"Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL (1989) Quality of life in panic disorder. Arch Gen Psychiatry 46:984\u2013992","journal-title":"Arch Gen Psychiatry"},{"key":"821_CR34","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1176\/ajp.155.11.1570","volume":"155","author":"D Michelson","year":"1998","unstructured":"Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD (1998) Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155:1570\u20131577","journal-title":"Am J Psychiatry"},{"key":"821_CR35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1192\/bjp.174.3.213","volume":"174","author":"D Michelson","year":"1999","unstructured":"Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G (1999) Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 174:213\u2013218","journal-title":"Br J Psychiatry"},{"key":"821_CR36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","volume":"179","author":"D Michelson","year":"2001","unstructured":"Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, Paunovic VR, Timotijevic I, Sarkar N, Skoglund L, Pemberton SC (2001) Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179:514\u2013518","journal-title":"Br J Psychiatry"},{"key":"821_CR37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.167.3.374","volume":"167","author":"S Oehrberg","year":"1995","unstructured":"Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167:374\u2013379","journal-title":"Br J Psychiatry"},{"key":"821_CR38","first-page":"207","volume":"34","author":"LA Papp","year":"1998","unstructured":"Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, Gorman JM (1998) Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34:207\u2013209","journal-title":"Psychopharmacol Bull"},{"key":"821_CR39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.jcp.0000125682.97466.3c","volume":"24","author":"G Perna","year":"2004","unstructured":"Perna G, Bertani A, Caldirola D, Di Pasquale D, Migliarese G, Bellodi L (2004) Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. J Clin Psychopharmacol 24:277\u2013282","journal-title":"Clin Psychopharmacol"},{"key":"821_CR40","first-page":"667","volume":"32","author":"MH Pollack","year":"1996","unstructured":"Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF (1996) Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32:667\u2013670","journal-title":"Psychopharmacol Bull"},{"key":"821_CR41","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","volume":"55","author":"MH Pollack","year":"1998","unstructured":"Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998) Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55:1010\u20131016","journal-title":"Arch Gen Psychiatry"},{"key":"821_CR42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S109285290000691X","volume":"8","author":"MH Pollack","year":"2003","unstructured":"Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP (2003) WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 8:17\u201330","journal-title":"CNS Spectr"},{"key":"821_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","volume":"24","author":"MH Pollack","year":"2007","unstructured":"Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas, E, Whitaker T, Gao B (2007) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24:1\u201314","journal-title":"Depress Anxiety"},{"key":"821_CR44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1034\/j.1600-0447.2001.00263.x","volume":"104","author":"MH Rapaport","year":"2001","unstructured":"Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2001) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104:289\u2013298","journal-title":"Acta Psychiatr Scand"},{"key":"821_CR45","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","volume":"157","author":"K Rickels","year":"2000","unstructured":"Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968\u2013974","journal-title":"Am J Psychiatry"},{"key":"821_CR46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","volume":"24","author":"K Rickels","year":"2004","unstructured":"Rickels K, Mangano R, Khan A (2004) Double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24:488\u2013496","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 4","key":"821_CR47","first-page":"16","volume":"66","author":"PP Roy-Byrne","year":"2005","unstructured":"Roy-Byrne PP, Wagner AW, Schraufnagel TJ (2005) Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry 66(Suppl 4):16\u201322","journal-title":"J Clin Psychiatry"},{"key":"821_CR48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4088\/JCP.v59n0305","volume":"59","author":"RL Rudolph","year":"1998","unstructured":"Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998) A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116\u2013122","journal-title":"J Clin Psychiatry"},{"key":"821_CR49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0924-977X(98)00024-8","volume":"9","author":"Y Sasson","year":"1999","unstructured":"Sasson Y, Iancu I, Fux LF, Taub M, Dannon PN, Zohar J (1999) A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 9:191\u2013196","journal-title":"Eur Neuropsychopharmacol"},{"key":"821_CR50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004850-200309000-00004","volume":"18","author":"S Seedat","year":"2003","unstructured":"Seedat S, van Rheede VO, Muller JE, Mohr N, Stein DJ (2003) Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 18:279\u2013284","journal-title":"Int Clin Psychopharmacol"},{"key":"821_CR51","first-page":"150","volume":"47","author":"DM Sharp","year":"1997","unstructured":"Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA (1997) Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 47:150\u2013155","journal-title":"Br J Gen Pract"},{"key":"821_CR52","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ajp.154.11.1571","volume":"154","author":"M Shear","year":"1997","unstructured":"Shear M, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA (1997) Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571\u20131575","journal-title":"Am J Psychiatry"},{"key":"821_CR53","volume-title":"The anxiety disease","author":"DV Sheehan","year":"1983","unstructured":"Sheehan DV (1983) The anxiety disease. Charles Scribners Sons, New York, NY"},{"key":"821_CR54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004714-198302000-00006","volume":"3","author":"DV Sheehan","year":"1983","unstructured":"Sheehan DV, Burnham DB, Iyengar MK, Perera P (1983) Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 3:28\u201331","journal-title":"J Clin Psychopharmacol"},{"key":"821_CR55","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22\u201333","journal-title":"J Clin Psychiatry"},{"key":"821_CR56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.v66n0105","volume":"66","author":"DV Sheehan","year":"2005","unstructured":"Sheehan DV, Burnham DB, Iyengar MK, Perera P (2005) Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 66:34\u201340","journal-title":"J Clin Psychiatry"},{"key":"821_CR57","first-page":"66","volume":"37","author":"NM Simon","year":"2003","unstructured":"Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, Pollack MH (2003) Bupropion sustained release for panic. Psychopharmacol Bull 37:66\u201372","journal-title":"Psychopharmacol Bull"},{"key":"821_CR58","first-page":"A11","volume":"15","author":"D Smith","year":"2001","unstructured":"Smith D (2001) The efficacy and tolerability of venlafaxine compared with other antidepressants in depression: a meta-analysis. J Psychopharmacol 15:A11","journal-title":"J Psychopharmacol"},{"key":"821_CR59","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","volume":"64","author":"SM Stahl","year":"2003","unstructured":"Stahl SM, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322\u20131327","journal-title":"J Clin Psychiatry"},{"key":"821_CR60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.178.3.234","volume":"178","author":"ME Thase","year":"2001","unstructured":"Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234\u2013241","journal-title":"Br J Psychiatry"},{"issue":"Suppl 1","key":"821_CR61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/PL00014164","volume":"249","author":"JW Tiller","year":"1999","unstructured":"Tiller JW, Bouwer C, Behnke K (1999) Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249(Suppl 1):7\u201310","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"821_CR62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.v63n0107","volume":"63","author":"M Versiani","year":"2002","unstructured":"Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31\u201337","journal-title":"J Clin Psychiatry"},{"key":"821_CR63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","volume":"170","author":"AG Wade","year":"1997","unstructured":"Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997) The effect of citalopram in panic disorder. Br J Psychiatry 170:549\u2013553","journal-title":"Br J Psychiatry"},{"key":"821_CR64","first-page":"6","volume":"52","author":"MM Weissman","year":"1991","unstructured":"Weissman MM (1991) Panic disorder: impact on quality of life. J Clin Psychiatry 52:6\u20138","journal-title":"J Clin Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-0821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-007-0821-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-007-0821-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:31:37Z","timestamp":1558629097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-007-0821-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,23]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,9,19]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s00213-007-0821-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,23]]}}}